Loading ZBH detail
Loading ticker data...
Loading ZBH detail
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S. E. T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015.
Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Chart data unavailable
Douglas Lane and Associates LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 6.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 460,178 shares of the medical equipment provider's stock after purchasing an additional 28,818 shares during
WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be webcast on Tuesday, April 28, 2026, at 8:30 a.m.
Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity WARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M.
Aberdeen Group plc reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 3.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 167,309 shares of the medical equipment provider's stock after selling 6,740 shares during
SNDL (NASDAQ: SNDL - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability. Risk and Volatility SNDL has a beta of 0.81,
First Community Trust NA lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 77.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,107 shares of the medical equipment provider's stock after selling 7,050 shares during the period. First Community Trust NA's
Zimmer Biomet Holdings, Inc. (NYSE: ZBH - Get Free Report) has been given a consensus rating of "Hold" by the twenty-two research firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, seven have given a buy rating and
SG Americas Securities LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 69.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 103,462 shares of the medical equipment provider's stock after purchasing an
ZBH leans on knee growth, robotics innovation and steady markets, but debt levels and stiff competition complicate its near-term investment appeal.
Pre-Market Stock Futures: Futures are trading higher after President Trump signalled that talks with Iran are progressing positively, as we get ready to start another trading week, with the same issues that have dragged the stock market down for four consecutive weeks still in place. While we have had a virtual March Madness in stocks,... Here Are Monday's Top Wall Street Analyst Research Calls: APA Corporation, Cheniere Energy, Crown Castle, Hut 8, MongoDB, Red Rock Resorts, Super Micro Computer, Terawulf, and More.
Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Profitability This table compares Capricor Therapeutics and Zimmer
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zimmer Biomet Holdings, Inc., (“Zimmer" or the "Company") (NYSE:ZBH) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zimmer Biomet Holdings, Inc. , (“ Zimmer " or the "Company") ( NYSE:ZBH ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zimmer Biomet Holdings, Inc., (“Zimmer" or the "Company") (NYSE:ZBH) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
